Chinook Therapeutics

Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Chinook Therapeutics is a biotechnology company that specializes in the fields of therapeutics and life science. The company focuses on developing precision medicines for kidney diseases. Its services offers utilization of novel translational platforms and patient stratification tools, and emergence of accelerated regulatory pathways based on surrogate endpoints.

SEATTLE, June 09, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Tom Frohlich, chief business officer, has been promoted to chief operating officer (COO) of Chinook and Andrew King, D.V.M, Ph.D., head of renal discovery and translational medicine, has been promoted to chief scientific officer (CSO) of Chinook.

Chinook Therapeutics Announces Promotions of Tom Frohlich to Chief Operating Officer and Andrew King, D.V.M, Ph.D., to Chief Scientific Officer

SEATTLE, June 08, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the presentation of data from the ongoing phase 1/2 study of BION-1301 in patients with IgAN. The findings were presented in an oral presentation at the 58th European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Virtual Congress.

Chinook Therapeutics Presents BION-1301 Interim Phase 1/2 Data in Patients with IgA Nephropathy (IgAN) at the 58th ERA-EDTA Virtual Congress

SEATTLE, May 25, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the company will host a live conference call and webcast on Tuesday, June 8, 2021 at 1:00 pm PDT to discuss the interim data from Part 3 of Chinook's ongoing phase 1b study of BION-1301 in patients with IgA nephropathy that will be presented at the 58th ERA-EDTA Congress. Members of the Chinook executive team will be joined by Dr. Jonathan Barratt, the Mayer Professor of Renal Medicine at University of Leicester.

Chinook Therapeutics to Host Conference Call and Webcast Featuring BION-1301 Data Presented at the 58th ERA-EDTA Congress

SEATTLE, May 12, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update and reported financial results for the first quarter ended March 31, 2021.

Chinook Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results

SEATTLE, April 15, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced six poster presentations at the ISN World Congress of Nephrology 2021 (WCN '21).

Chinook Therapeutics Presents Data During the ISN World Congress of Nephrology 2021

SEATTLE, April 07, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update and reported financial results for the full year ended December 31, 2020.

Chinook Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

Data from Initial Patient Cohorts of Phase 2 AFFINITY Study Expected to be Reported in 2022

Chinook Therapeutics Announces First Patient Dosed in Phase 2 AFFINITY Basket Study of Atrasentan in Proteinuric Glomerular Diseases

Van Herk Investments to Form and Invest in Sairopa, a New Company Focused on Research and Development of B-Select Monoclonal Antibody Platform Programs

Chinook Therapeutics Announces Update on Non-Renal Legacy Programs from Aduro Biotech Merger

Chinook (KDNY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Chinook (KDNY) Surges 7%: Is This an Indication of Further Gains?

VANCOUVER, British Columbia and SEATTLE, March 30, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced upcoming data presentations at the ISN World Congress of Nephrology 2021 from April 15 – 19, 2021 and the 58th ERA-EDTA Congress from June 5 – 8, 2021.

Chinook Therapeutics Announces Upcoming Data Presentations at ISN World Congress of Nephrology 2021 and 58th ERA-EDTA Congress

Phase 2 AFFINITY Trial of Atrasentan for Patients with Glomerular Diseases Also on Track to Begin Enrollment in the First Half of 2021

Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 ALIGN Study of Atrasentan for Patients with IgA Nephropathy

Chinook (KDNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Chinook Therapeutics (KDNY) Report Negative Q4 Earnings? What You Should Know

VANCOUVER, British Columbia and SEATTLE, March 01, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY) and Evotec SE today announced a strategic collaboration focused on the discovery and development of novel precision medicine therapies for patients with chronic kidney diseases. Based on Evotec's proprietary comprehensive molecular datasets from thousands of patients across chronic kidney diseases of multiple underlying etiologies, Chinook and Evotec will jointly identify, characterize and validate novel mechanisms and discover precision medicines for PKD, lupus nephritis, IgA nephropathy and other primary glomerular diseases. The collaboration will also involve further characterization of pathways and patient stratification strategies for programs currently in Chinook's clinical and preclinical pipeline.

Chinook Therapeutics and Evotec Announce Strategic Collaboration to Discover and Develop Novel Precision Medicines for Chronic Kidney Diseases

Chinook Therapeutics Inc (NASDAQ: KDNY) and Evotec SE (OTCMKTS: EVTCY) have collaborated for the discovery and development of precision medicine therapies for patients with chronic kidney diseases (CKD). Based on Evotec's proprietary comprehensive molecular datasets, Chinook and Evotec will jointly identify, characterize and validate novel mechanisms and discover and develop precision medicines.

Evotec, Chinook Therapeutics Ink Development Pact For Chronic Kidney Diseases Therapies

Head of Renal Discovery and Translational Medicine, Andrew King, D.V.M., Ph.D., to Present on Atrasentan and Participate in Expert Panel Discussion on Executing Precision Medicine in Clinical Trials

Chinook Therapeutics to Present at 3rd Annual Chronic Kidney Disease Drug Development (CKD3) Summit

VANCOUVER, British Columbia and SEATTLE, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in a virtual fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 24, 2021 at 10:00 am ET.

Chinook Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference

The FDA has granted Rare Pediatric Disease status to Chinook Therapeutics Inc's (NASDAQ: KDNY) CHK-336, an investigational oral small molecule inhibitor of lactate dehydrogenase A for primary hyperoxaluria (PH), a rare genetic disorder that mainly affects the kidneys and results from a buildup of a substance called oxalate.

Chinook Therapeutics Nabs Rare Pediatric Disease Tag For CHK-336 In Primary Hyperoxaluria

CHK-336 On Track for Phase 1 Clinical Trial Initiation in the Second Half of 2021

Chinook Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for CHK-336 for Treatment of Primary Hyperoxaluria

VANCOUVER, British Columbia and SEATTLE, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that it has entered into a license agreement with Morehouse School of Medicine for certain patents supporting the development of therapeutics in kidney diseases that disproportionately affect people of West African descent and underserved communities.

Chinook Therapeutics Announces License Agreement with Morehouse School of Medicine for Development of Therapies in Kidney Diseases Disproportionately Affecting African Americans and Underserved Communities

News for Chinook Therapeutics Stock (KDNY)